Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages.
Citations
744 citations
Cites background from "Phosphatidylserine-containing lipos..."
...Furthermore, recent studies have shown that liposome administration can alter macrophage phenotype in vivo in part by induction of ERK signaling after ingestion (53, 54)....
[...]
152 citations
Cites background from "Phosphatidylserine-containing lipos..."
...[77] suggests that this effect is due to increased IL-10 production by macrophages....
[...]
70 citations
64 citations
Cites background from "Phosphatidylserine-containing lipos..."
...In vivo, PSLs have been described to promote the resolution of inflammation by modulating macrophage function in a model for inflammatory bone loss and myocardial infarction [31,33]....
[...]
...In vitro, clearance of apoptotic cells and PSLs skews macrophages towards a tolerogenic phenotype [21,23,29-35]....
[...]
55 citations
References
49 citations
"Phosphatidylserine-containing lipos..." refers methods in this paper
...The PSL-treated or untreated macrophage extracts were prepared with cell lysis buffer as described previously.(13) A...
[...]
...PSLs and PCLs were prepared as described previously.(13) In some experiments,...
[...]
49 citations
"Phosphatidylserine-containing lipos..." refers background in this paper
...Among anti-inflammatory mediators, including TGF-b1 and PGE2, IL-10 is known as the strongest feedback mediator of inflammatory bone loss.(23,24)...
[...]
47 citations
43 citations
42 citations